Category: Health
The FDA approved Journavx (suzetrigine) as a first-in-class non-opioid analgesic for treating acute pain in adults, marking a significant milestone in pain management and providing an alternative to opioids. This approval follows a rise in opioid-related overdose deaths, emphasizing the need for safer pain management options.
Keywords: FDA, Journavx, non-opioid analgesic
Source: WJHL-TV News Channel 11
Update At: 2/1/2025